Department of Medicinal Chemistry, University of Kansas, 1567 Irving Hill Road, GLH-2115, Lawrence, KS 66045, USA.
Molecules. 2021 Jan 13;26(2):388. doi: 10.3390/molecules26020388.
The membrane-embedded γ-secretase complex carries out hydrolysis within the lipid bilayer in proteolyzing nearly 150 different membrane protein substrates. Among these substrates, the amyloid precursor protein (APP) has been the most studied, as generation of aggregation-prone amyloid β-protein (Aβ) is a defining feature of Alzheimer's disease (AD). Mutations in APP and in presenilin, the catalytic component of γ-secretase, cause familial AD, strong evidence for a pathogenic role of Aβ. Substrate-based chemical probes-synthetic peptides and peptidomimetics-have been critical to unraveling the complexity of γ-secretase, and small drug-like inhibitors and modulators of γ-secretase activity have been essential for exploring the potential of the protease as a therapeutic target for Alzheimer's disease. Such chemical probes and therapeutic prototypes will be reviewed here, with concluding commentary on the future directions in the study of this biologically important protease complex and the translation of basic findings into therapeutics.
膜嵌入的 γ-分泌酶复合物在水解过程中在脂质双层内进行,可蛋白水解近 150 种不同的膜蛋白底物。在这些底物中,淀粉样前体蛋白 (APP) 是研究最多的,因为易于聚集的淀粉样 β 蛋白 (Aβ) 的产生是阿尔茨海默病 (AD) 的一个特征。APP 和 γ-分泌酶的催化成分早老素中的突变会导致家族性 AD,这有力地证明了 Aβ 的致病作用。基于底物的化学探针-合成肽和肽类似物-对于揭示 γ-分泌酶的复杂性至关重要,而小分子类药物抑制剂和 γ-分泌酶活性调节剂对于探索该蛋白酶作为治疗 AD 的治疗靶点的潜力至关重要。在这里,我们将对这些化学探针和治疗原型进行综述,并对这一具有重要生物学意义的蛋白酶复合物的研究方向以及基础研究发现转化为治疗方法进行总结评论。